Skip to content

OncoRNA

Active
Public limited companyfounded 20233 yrs activeRue Louis Breguet 1, 6041 Charleroi, BelgiumKBO/BCE: BE 0805.162.158
Summary

The computed 12-month bankruptcy probability of OncoRNA is 1.9% (moderate). The 2025 annual accounts show negative equity (-€31,846) and a net result of -€15,560. Equity is shrinking by ~122.4% per year across the filed fiscal years. Its solvency ranks better than 8% of 216 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.

Checked score

Score 2025
Axes · tick = 2024
Profitability0=
Solvency0=
Growth58=
Track record94
Bankruptcy probability, 12 months
1.9% Moderate
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.39 against 0.5 in 2024; short-term debt: 259% and cash: 97% of total assets), and equity is negative.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 3 years 0 10 y
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-159%
Return on assets
-77.7%
Age of the figures
9 mo
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
232425
2023 to 2025 · latest year -€31,846
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-07-2026, 17 days ahead of the deadline.
NBB · 3 filings
Deviation from the deadline
2025
17 d early
2024
1 d early
2023
65 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 16 days after the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 30 July (3 of the last 3 filed years within 67 days of that day).
Companies Code · seven months
Position in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

On 28 August 2023, OncoRNA was incorporated as a Public limited company.1 Total assets went from EUR 27,837 in 2023 to EUR 20,034 in 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2023 and 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, abbreviated schema

Equity
-€31,846▼ 95.5%
2024 · -€16,286
Total assets
€20,034▲ 20.7%
2024 · €16,596
Net result
-€15,560▲ 59.3%
2024 · -€38,269
Working capital
-€31,846▼ 95.5%
2024 · -€16,286
Trend over the years

Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.

Every figure with its change against the fiscal year before
favourable unfavourable
Line202320242025
Operating result-€39,247--€37,815▲ 3.6%-€15,141▲ 60.0%
Net result-€39,517below the sector's middle half--€38,269below the sector's middle half▲ 3.2%-€15,560within the sector's middle half▲ 59.3%
Equity€21,983below the sector's middle half--€16,286below the sector's middle half-€31,846below the sector's middle half▼ 95.5%
Total assets€27,837below the sector's middle half-€16,596below the sector's middle half▼ 40.4%€20,034below the sector's middle half▲ 20.7%
Debt€5,854-€32,882▲ 462%€51,880▲ 57.8%
Working capital€21,983within the sector's middle half--€16,286below the sector's middle half-€31,846below the sector's middle half▼ 95.5%
Solvency79.0%within the sector's middle half--98.1%below the sector's middle half▼ 177.1pp-159.0%below the sector's middle half▼ 60.8pp
Current ratio4.76within the sector's middle half-0.50below the sector's middle half▼ 4.250.39below the sector's middle half▼ 0.12
Return on assets (ROA)-142.0%below the sector's middle half--230.6%below the sector's middle half▼ 88.6pp-77.7%below the sector's middle half▲ 152.9pp
above within below the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
-€40,000-€30,000-€20,000-€10,000€0Operating result 2023: -€39,247-€39,247Net result 2023: -€39,517-€39,517Operating result 2024: -€37,815-€37,815Net result 2024: -€38,269-€38,269Operating result 2025: -€15,141-€15,141Net result 2025: -€15,560-€15,560202320242025-€40,000-€30,000-€20,000-€10,000€0Operating result 2023: -€39,247-€39,200Net result 2023: -€39,517-€39,500Operating result 2024: -€37,815-€37,800Net result 2024: -€38,269-€38,300Operating result 2025: -€15,141-€15,100Net result 2025: -€15,560-€15,600202320242025
The operating result stays negative: a loss of €15,141 in 2025 against €37,815 in 2024; the loss shrinks.
Key figures and ratios
2025 value · change against 2024
Debt to equity
-1.63▲
2024 · -2.02
Debt ≤ 1 year
€51,880▲
2024 · €32,882
Staff costs
-€340▼
2024 · €1,238
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 7,657 companies that looked in July 2024 the way this one looks now, 8.2% went bankrupt within 24 months and 84% are still going.

  • Micro
  • 2 to 5 years old
  • negative equity
  • a loss of 10% of the balance sheet or more
8.2% went bankrupt
5.3% stopped otherwise
84% still going

A further 2.0% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 1.9% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.7%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 7,657 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 28 lines
Balance sheet Code20242025
Assets
Total assets20/58€16,596€20,034▲
Current assets29/58€16,596€20,034▲
Amounts receivable within one year40/41€1,569€610▼
Trade receivables40-€167
Other amounts receivable41€1,569€443▼
Cash at bank and in hand54/58€15,028€19,424▲
Equity and liabilities
Total equity and liabilities10/49€16,596€20,034▲
Equity10/15-€16,286-€31,846▼
Contributions10/11€61,500€61,500=
Capital10€61,500€61,500=
Issued capital100€61,500€61,500=
Profit (loss) carried forward14-€77,786-€93,346▼
Amounts payable17/49€32,882€51,880▲
Amounts payable within one year42/48€32,882€51,880▲
Trade debts44€6,002-
Suppliers440/4€6,002-
Other amounts payable47/48€26,880€51,880▲
Income statement Code20242025
Remuneration, social security and pensions62€1,238-€340▼
Other operating charges640/8€271€244▼
Gross operating margin9900-€36,306-€15,237▲
Operating profit (loss)9901-€37,815-€15,141▲
Financial charges65/66B€454€420▼
Recurring financial charges65€454€420▼
Profit (loss) for the period before taxes9903-€38,269-€15,560▲
Profit (loss) for the period9904-€38,269-€15,560▲
Profit (loss) for the period to be appropriated9905-€38,269-€15,560▲
Appropriation of the result
Profit (loss) to be appropriated9906-€77,786-€93,346▼
Profit (loss) brought forward from the previous period14P-€39,517-€77,786▼
Line202320242025Change
Remuneration, social security and pensions62-€1,238-€340▼ 127%
Other operating charges640/8€1,301€271€244▼ 10.0%
Gross operating margin9900-€37,946-€36,306-€15,237▲ 58.0%
Operating profit (loss)9901-€39,247-€37,815-€15,141▲ 60.0%
Financial charges65/66B€270€454€420▼ 7.5%
Recurring financial charges65€270€454€420▼ 7.5%
Profit (loss) for the period before taxes9903-€39,517-€38,269-€15,560▲ 59.3%
Profit (loss) for the period9904-€39,517-€38,269-€15,560▲ 59.3%
Profit (loss) for the period to be appropriated9905-€39,517-€38,269-€15,560▲ 59.3%
Line202320242025Change
Assets
Total assets20/58€27,837€16,596€20,034▲ 20.7%
Current assets29/58€27,837€16,596€20,034▲ 20.7%
Amounts receivable within one year40/41€3,890€1,569€610▼ 61.1%
Trade receivables40--€167-
Other amounts receivable41€3,890€1,569€443▼ 71.8%
Cash at bank and in hand54/58€23,947€15,028€19,424▲ 29.3%
Equity and liabilities
Total equity and liabilities10/49€27,837€16,596€20,034▲ 20.7%
Equity10/15€21,983-€16,286-€31,846▼ 95.5%
Contributions10/11€61,500€61,500€61,500=
Capital10€61,500€61,500€61,500=
Issued capital100€61,500€61,500€61,500=
Profit (loss) carried forward14-€39,517-€77,786-€93,346▼ 20.0%
Amounts payable17/49€5,854€32,882€51,880▲ 57.8%
Amounts payable within one year42/48€5,854€32,882€51,880▲ 57.8%
Trade debts44€5,853€6,002--
Suppliers440/4€5,853€6,002--
Other amounts payable47/48€1€26,880€51,880▲ 93.0%
Line202320242025Change
Profit (loss) for the period9904-€39,517-€38,269-€15,560▲ 59.3%
Operating cash flow (approximation)-€39,517-€38,269-€15,560▲ 59.3%
Change in cash--€8,919€4,397▲ 149%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
31-08
State Gazette act Permanent representatives: Charles-André Brouwers, Bernard Courtieu and François Fontaine
Resignation: Société Fédérale de Participations et d'Investissement (SFPI) (director) · Power of attorney8 facts ▸
  • Permanent representative, Charles-André Brouwers (permanent representative)
  • Permanent representative, Bernard Courtieu (permanent representative)
  • Director resignation, Société Fédérale de Participations et d'Investissement (SFPI) (director)
  • Permanent representative, François Fontaine (permanent representative)
  • Power of attorney, Hadrien Chef
  • Power of attorney, Violette Keppenne
  • Power of attorney, Mathilde Drion
  • Power of attorney, Sofia Ballesteros Garcia
14-07
NBB filing Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
30-07
NBB filing Annual accounts filed
fiscal year 2024 · micro schema
2024
04-10
NBB filing Annual accounts filed
fiscal year 2023 · micro schema · 65 days late
State Gazette actNBB filing
1 of 2 acts read
About the unread acts

Of the 2 Belgian State Gazette acts we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
no sitting director, last change in 2024
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
Not every act has been read: a resignation may be missing here
1 of this company's 2 Belgian State Gazette acts has not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Charleroi · 1 establishment unit since 2023
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Rue Louis Breguet 16041 Charleroi
1 establishment unit
OncoRNA
Rue Louis Breguet 1, 6041 CharleroiManufacture of basic pharmaceutical products and pharmaceutical preparations
since 20232.348.914.881

Mandate history

1 person since 2024, 0 in office
Show
  • Board
  • began earlier
Mandates per person, with start and end dates
Name Functions and periods
SOCIETE FEDERALE DE PARTICIPATIONS ET D'INVESTISSEMENT
  • Director, until 30-09-2024
See the board, name and seat on a given date →

Similar companies · same sector, comparable size

Of 762 companies in sector 72101 we hold annual accounts for 484. 188 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded28-08-2023
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
E-invoicing
Reachable via Peppol
Peppol ID 0208:0805162158
Registered 25-11-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 28 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.